We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Global Point-of-Care (POC) Testing Market to Reach Nearly USD 80 Billion by 2028 due to Increasing Dominance of Infectious Diseases

By LabMedica International staff writers
Posted on 15 Oct 2021
Print article

The global Point-Of-Care (POC) testing market is projected to grow at a CAGR of 12.3% from USD 31.17 billion in 2020 to USD 78.85 billion by 2028, driven mainly by the increasing dominance of infectious diseases, hematological diseases, cancer, and others.

These are the latest findings of Zion Market Research (New York, NY, USA), a global market research company.

POC testing devices are mainly used for diagnosis of disease for early detection and monitoring along with its effective treatment and management. During the last few decades, there has been a significant growth in the pervasiveness of chronic diseases which has led to an upsurge in patient inflow. POC tests are beneficial in providing instantaneous results to the patient. However, the introduction of new tests and devices in the market require manufacturers to meet strict government regulations. These stringent government regulations and poor reimbursement policies could hinder the growth of the global POC testing market. The decentralization of healthcare is one of the major trends being currently observed in patient care and is anticipated to offer new market growth opportunities.

The COVID-19 pandemic has accelerated the global demand for diagnostic kits for rapid detection of the diseases. As a result, several market players are focusing on increasing the supply of tests worldwide. Owing to an increase in chronic diseases and patients suffering from such diseases, there is growing healthcare awareness among people which is also fueling the growth of the POC testing market. Increasing government support, along with the rising number of clinics adopting POC tests for the rapid detection of infectious diseases in the near future are expected to continue driving the growth of the POC testing market during the forecast period. However, multi-layered regulations set by the FDA and laboratory regulations under CLIA could restrain the market growth.

Nevertheless, greater acceptance of new technologies among researchers and academia, technological advancements, large base of population suffering from chronic and acute diseases, and increasing number of end users such as hospitals and clinics, outpatient & ambulatory care facilities are likely to continue driving the growth of the global POC testing market.

Geographically, North America holds the largest share of the global POC testing market owing to its huge patient population, well developed economies and high healthcare expenditure. Additionally, North America is also home to the key market players, supportive governments, people with higher awareness of self-testing and home care products, and a population that has significant adoption of novel technologies. On the other hand, Asia Pacific is anticipated to be the fastest growing market for POC testing due to its huge population base.

Related Links:
Zion Market Research 

Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
Bulk Sorter
Tuberculosis (TB) Test
QIAreach QuantiFERON-TB
6-Channel Viscoelastometry Analyzer

Print article


Molecular Diagnostics

view channel
Image: Absence of nuclear immunohistochemical staining of MSH2 protein (A) and presence of MLH1 protein (B) in urothelial cell carcinoma of the urinary bladder of a patient carrying a germline MSH2 mutation. Observe the nuclear staining in stromal cells as an internal control (Photo courtesy of Radboud University Nijmegen Medical Centre)

Simple Urine Test Detects Urothelial Cancers in Lynch Syndrome Patients

Lynch Syndrome (LS) is an inherited genetic disorder that carries a high risk of cancer. LS is caused by mutations affecting MLH1, MSH2, MSH6 or PMS2 genes. More than one in 300 people have LS but most... Read more


view channel
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin... Read more


view channel
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results... Read more


view channel
Image: The sciREADER CL2 enables high quality digital colorimetric imaging of various support formats (Photo courtesy of SCIENION)

Multiplex Immunoassay Developed for Confirmation and Typing of HTLV Infections

Human T-Cell Lymphotropic Viruses (HTLV) type 1 and type 2 account for an estimated five to 10 million infections worldwide and are transmitted through breast feeding, sexual contacts and contaminated... Read more


view channel

AI Accurately Detects and Diagnoses Colorectal Cancer from Tissue Scans As Well or Better Than Pathologists

Artificial intelligence (A) can accurately detect and diagnose colorectal cancer from tissue scans as well or better than pathologists, according to a new study. The study, which was conducted by researchers... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.